U.S. markets closed

Veracyte, Inc. (VCYT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
62.30+0.79 (+1.28%)
At close: 4:00PM EST

62.30 0.00 (0.00%)
After hours: 4:33PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close61.51
Open61.95
Bid52.00 x 800
Ask62.40 x 900
Day's Range59.57 - 64.80
52 Week Range13.90 - 86.03
Volume856,084
Avg. Volume865,201
Market Cap4.174B
Beta (5Y Monthly)0.69
PE Ratio (TTM)N/A
EPS (TTM)-0.66
Earnings DateMay 04, 2021 - May 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est84.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference
    Business Wire

    Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference

    Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference

  • Benzinga

    Veracyte: Q4 Earnings Insights

    Shares of Veracyte (NASDAQ:VCYT) were unchanged in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 6.67% over the past year to ($0.14), which missed the estimate of ($0.11). Revenue of $34,536,000 up by 16.17% year over year, which beat the estimate of $31,930,000. Guidance Veracyte Sees FY21 Sales $190M-$200M Vs. $151.18M Est. Conference Call Details Date: Feb 17, 2021 Time: 05:30 PM View more earnings on VCYT ET Webcast URL: https://edge.media-server.com/mmc/p/p7geixt9 Price Action 52-week high: $86.03 Company's 52-week low was at $13.90 Price action over last quarter: Up 93.62% Company Profile Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis product. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 17, 2021Earnings Outlook For Veracyte© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results
    Business Wire

    Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results

    Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results